ClinicalTrials.gg
RecruitingNCT07636590Updated Nov 18, 2026

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

An observational study in Limbal Stem Cell Deficiency, sponsored by Claris Biotherapeutics, Inc.. Recruiting at 21 sites in United States. Open to participants aged 12 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Claris Biotherapeutics, Inc. · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 18, 202613 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
12 Years to 99 Years
Sex
All
01

Study summary

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

02

Conditions studied

  • Limbal Stem Cell Deficiency
03

In context

Limbal Stem Cell Deficiency

38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.

This study's planned enrollment of 500 is above the median of 69 across 12 observational studies indexed under Limbal Stem Cell Deficiency.

Browse Limbal Stem Cell Deficiency studies →

Lead sponsor

Claris Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult and adolescent subjects with qualifying LSCD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A photopic BCVA in the prospective study eye(s) of ≤ 70 letters at the Screening and Day 1 visits AND a change of ≤ 10 letters in photopic BCVA at Day 1 compared to the Screening Visit
  • Qualifying LSCD diagnosis in the study eye(s) prior to enrollment at Day 1
  • Written confirmation that exclusions on retinal findings are met in the study eye(s) prior to enrollment at Day 1
  • Inflammation associated with LSCD or other non-infectious inflammation (e.g., dry eye, ocular rosacea, and blepharitis) that will not interfere with the subject's participation in the opinion of the investigator is permitted.

Exclusion criteria

Exclusion Criteria:

  • Any active ocular infection in either eye at either the Screening or Day 1 visits
  • Active sterile iritis or uveitis in either eye at Screening or Day 1 visits
  • Screening visit retinal exam finding, in the opinion of the investigator, that would limit potential for visual acuity gain in the study eye(s)

Note: Other inclusion/exclusion criteria apply.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Non-interventional

    No product administration.

    Other: Non-interventional

Interventions

  • OtherNon-interventional

    Non-interventional

06

What researchers measure

Primary outcomes

  1. Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes

    Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires

    Time frame: Screening through Week 84

  2. Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)

    Change in photophobic BCVA

    Time frame: Screening through Week 84

  3. Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)

    Change in low-luminance BCVA

    Time frame: Screening through Week 84

  4. Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)

    Change in low-contrast BCVA

    Time frame: Screening through Week 84

  5. Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)

    Change in contrast sensitivity (Pelli-Robson)

    Time frame: Screening through Week 84

  6. Natural Progression of LSCD as Assessed by Anatomical/Structural Changes

    Change in area of central cornea conjunctivalization

    Time frame: Screening through Week 84

Secondary outcomes

  1. Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)

    Changes (onset, improvement, or worsening) in corneal sensitivity

    Time frame: Screening through Week 84

  2. Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)

    Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry

    Time frame: Screening through Week 84

  3. Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)

    Changes (onset, improvement, or worsening) in epithelial defect frequency

    Time frame: Screening through Week 84

  4. Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)

    Changes (onset, improvement, or worsening) in Palisades of Vogt crypts

    Time frame: Screening through Week 84

  5. Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)

    Changes (onset, improvement, or worsening) in epithelial and total corneal thickness

    Time frame: Screening through Week 84

  6. Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)

    Changes (onset, improvement, or worsening) in pannus

    Time frame: Screening through Week 84

  7. Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures

    Changes (onset, improvement/resolution, or worsening) of an existing condition

    Time frame: Screening through Week 84

07

Study locations

21 of 21 sites recruiting
  • Claris Investigative Site
    Huntington Beach, California 92647, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    La Jolla, California 92037, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Los Angeles, California 90048, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Tampa, Florida 33603, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Carmel, Indiana 46290, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Indianapolis, Indiana 46260, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Overland Park, Kansas 66204, United States
    Recruiting
    • Study Coordinator · Contact
  • Claris Investigative Site
    Wichita, Kansas 67206, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Louisville, Kentucky 40206, United States
    Recruiting
    • Study Coordinator · Contact
  • Claris Investigative Site
    South Dartmouth, Massachusetts 02747, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Minnetonka, Minnesota 53052, United States
    Recruiting
    • Study Coordinator · Contact
  • Claris Investigative Site
    Kansas City, Missouri 64154, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Palisades Park, New Jersey 07650, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Rockville Centre, New York 11570, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Portland, Oregon 97210, United States
    Recruiting
    • Study Coordinator · Contact
  • Claris Investigative Site
    Cranberry Township, Pennsylvania 16066, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Sioux Falls, South Dakota 57108, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Smyrna, Tennessee 37167, United States
    Recruiting
    • Study Coordinator · Contact
  • Claris Investigative Site
    San Antonio, Texas 78212, United States
    Recruiting
    • Study Coordinator · Contact
  • Claris Investigative Site
    Draper, Utah 84020, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
  • Claris Investigative Site
    Norfolk, Virginia 23502, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact919-205-0012
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Mar 2028, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 9, 2026
StartActual
May 22, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added
Show 13 added (13 United States)
  • Claris Investigative Site · Huntington Beach, United States
  • Claris Investigative Site · La Jolla, United States
  • Claris Investigative Site · Los Angeles, United States
  • Claris Investigative Site · Tampa, United States
  • Claris Investigative Site · Wichita, United States
  • Claris Investigative Site · South Dartmouth, United States
  • Claris Investigative Site · Kansas City, United States
  • Claris Investigative Site · Palisades Park, United States
  • Claris Investigative Site · Rockville Centre, United States
  • Claris Investigative Site · Cranberry Township, United States
  • Claris Investigative Site · Sioux Falls, United States
  • Claris Investigative Site · Draper, United States
  • Claris Investigative Site · Norfolk, United States
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    13 sites added
    Show 13 added (13 United States)
    • Claris Investigative Site · Huntington Beach, United States
    • Claris Investigative Site · La Jolla, United States
    • Claris Investigative Site · Los Angeles, United States
    • Claris Investigative Site · Tampa, United States
    • Claris Investigative Site · Wichita, United States
    • Claris Investigative Site · South Dartmouth, United States
    • Claris Investigative Site · Kansas City, United States
    • Claris Investigative Site · Palisades Park, United States
    • Claris Investigative Site · Rockville Centre, United States
    • Claris Investigative Site · Cranberry Township, United States
    • Claris Investigative Site · Sioux Falls, United States
    • Claris Investigative Site · Draper, United States
    • Claris Investigative Site · Norfolk, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07636590
Lead sponsor
Claris Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
May 22, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Central Operations Representative
Contact
clinicaltrials@clarisbio.com
949-354-1299

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion